Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 460 participants.
Also called NCT01068665
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 460 participants
- Sponsor
- Registry
-
NCT01068665 -
2009-010662-28
-
- Main results
- Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, France, Ireland, Russia, South Africa, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01068665. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2010-11 (actual). Results posted on 2015-11-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
- Acronym
- BEGIN™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01068665- Content hash
c5a48fb8d80d07afc7d6d935f18a3bd7198d1ebef4d3b3cdb962ef9e3bb2edff